The long-term objective for the new Clinical Immunobiology Correlative Studies Laboratory (CICSL) is to develop into a comprehensive, cutting-edge correlative studies laboratory to support clinical trial and translational research efforts sponsored primarily by Cancer Center investigators at City of Hope. Long-term specific aims include i) continued development and implementation of novel immunological platforms and assays, identified either from external sources or internally, that will support, in a significant way, ongoing and future clinical trials;ii) continued expansion of user base to reflect support, in magnitude and diversity, of the majority of correlative assay needs of Cancer Center investigators;iii) continued evolution and implemention of laboratory operating policies and infrastructure to adhere to GLP practices and ultimately lead to CLIA certification of the laboratory. The principle objective of the laboratory is to develop and implement quantitative methods to evaluate the effect of novel therapies on a patient's immune system, and correlate those effects with treatment outcome to guide the rational development of efficacious therapeutic regimens. The research design and methods for the laboratory are to identify technology platforms that would be most useful and appropriate to evaluate the effect of therapeutic modalities on patients, and to develop assays based on those platforms that could be used to evaluate clinical trials sponsored by Cancer Center investigators. To that end, the laboratory has expertise and infrastructure to develop molecular, flowbased and cell-based assays. The laboratory operates under GLP guidelines, a fact that supports a high standard of operations. During the most recent 10-month reporting period, the CICSL shared resource was used by 13 Cancer Center members from all 5 programs. Peer-reviewed usage represented 79% of total usage. Annual budget for this core is $603,900, of which 47% is institutional funding, 28% is user fees, 15% is from other sources, and 10% ($60,100) is requested from the CCSG.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076

Showing the most recent 10 out of 1277 publications